129 related articles for article (PubMed ID: 22873503)
1. Oxaliplatin-induced lung toxicity. Case report and review of the literature.
Prochilo T; Abeni C; Bertocchi P; Zaniboni A
Curr Drug Saf; 2012 Apr; 7(2):179-82. PubMed ID: 22873503
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
[No Abstract] [Full Text] [Related]
3. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials.
Xu HB; Huang F; Su R; Shen FM; Lv QZ
Eur J Clin Pharmacol; 2015 May; 71(5):589-601. PubMed ID: 25795200
[TBL] [Abstract][Full Text] [Related]
4. Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.
Baek YH; Choi SR; Jang JS; Roh MH; Lee JH; Won JJ; Lee CM
Hepatogastroenterology; 2011; 58(105):251-6. PubMed ID: 21510324
[TBL] [Abstract][Full Text] [Related]
5. [Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].
Park S; Jung JJ; Kim GB; Yoon HS; Ko SH; Ko JE; Lee YS
Korean J Gastroenterol; 2010 May; 55(5):340-3. PubMed ID: 20697195
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
Garrido M; Melgoza G; Galindo H; Madrid J; Sánchez C; Nervi B; Alvarez M; Orellana E
Rev Med Chil; 2007 Nov; 135(11):1380-7. PubMed ID: 18259648
[TBL] [Abstract][Full Text] [Related]
8. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
De Vita F; Orditura M; Matano E; Bianco R; Carlomagno C; Infusino S; Damiano V; Simeone E; Diadema MR; Lieto E; Castellano P; Pepe S; De Placido S; Galizia G; Di Martino N; Ciardiello F; Catalano G; Bianco AR
Br J Cancer; 2005 May; 92(9):1644-9. PubMed ID: 15856038
[TBL] [Abstract][Full Text] [Related]
11. Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer.
Amini A; Sanati H
Anticancer Drugs; 2011 Nov; 22(10):1024-6. PubMed ID: 21822120
[TBL] [Abstract][Full Text] [Related]
12. Fatal pneumonitis induced by oxaliplatin.
Arévalo Lobera S; Sagastibeltza Mariñelarena N; Elejoste Echeberría I; Melé Olivé M; Egaña Otaño L; Basterretxea Badiola L; La Casta Muñoa A; Azkue Gabilondo M
Clin Transl Oncol; 2008 Nov; 10(11):764-7. PubMed ID: 19015075
[TBL] [Abstract][Full Text] [Related]
13. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
Mohammad HA; Magdy FM; Mahmoud OM
Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Wang ZH; Guo J; Chen Z; Li CZ; Sheng LJ; Zhou DG; Liu B; Liu J; Wang QC; Zhang EN
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):389-91. PubMed ID: 18953843
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease associated with FOLFOX chemotherapy.
Lim JH; Kim H; Choi WG; Lee MH
J Cancer Res Ther; 2010; 6(4):546-8. PubMed ID: 21358098
[TBL] [Abstract][Full Text] [Related]
16. [FOLFOX].
Mishima H; Ikenaga M; Tsujinaka T; Yasui M; Kashiwazaki M; Miyazaki M; Hirao M; Fujitani K; Nakamori S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):911-4. PubMed ID: 16835479
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
Laterza MM; Pompella L; Petrillo A; Tirino G; Pappalardo A; Orditura M; Troiani T; Ciardiello F; Di Martino N; De Vita F
Med Oncol; 2017 Oct; 34(11):186. PubMed ID: 29043514
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Said R; Ye Y; Hong DS; Naing A; Falchook G; Fu S; Wheler JJ; Piha-Paul S; Tsimberidou AM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):575-81. PubMed ID: 26825327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
